UPDATED: May 8, 2021 16:19 IST
An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by DRDO in collaboration with Dr Reddy’s Laboratories, Hyderabad. (Photo: India Today/Manjeet Negi)
The Drugs Controller General of India (DCGI) has approved the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 patients.
The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients, DRDO said in an official s
DRDO s Anti-Covid Drug Gets DCGI s Nod For Emergency Use The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients, the defence ministry said.
The drug comes in powder form in a sachet and is taken orally by dissolving it in water. (Representational image.) Outlook Web Bureau 2021-05-08T16:46:22+05:30 DRDO s Anti-Covid Drug Gets DCGI s Nod For Emergency Use outlookindia.com 2021-05-08T16:50:27+05:30
Also read
The Drugs Controller General of India (DCGI) on Saturday approved the emergency use of an anti-Covid oral drug developed by the DRDO that can be used in treatment of moderate to severe Covid patients.
DRDO s anti-COVID drug approved for emergency use
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by DRDO in collaboration with Dr Reddy s Laboratories, Hyderabad
BusinessToday.In | May 8, 2021 | Updated 16:22 IST
The Drugs Controller General of India (DCGI) has approved teh emergency use of drug 2-deoxy-D-glucose (2-DG) developed by DRDO
The Drugs Controller General of India (DCGI) on Saturday gave approval to the anti-COVID drug developed by DRDO (Defence Research and Development Organisation) for emergency use.
The drug, 2-deoxy-D-glucose (2-DG), to treat coronavirus patients has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy s Laboratories, Hyderabad.
DRDO s anti-COVID drug reducing oxygen dependence approved for emergency use
Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: The Drugs Controller General of India (DGCI) has granted emergency use approval to an anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation(DRDO) lab. This after a three-phase clinical trial of the drug had shown a faster recovery of hospitalised patients.
The Ministry of Defence on Saturday informed that Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.
An anti-COVID oral drug developed by the DRDO has been approved by the Drugs Controller General of India (DCGI) for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said on Saturday.
Clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence, it said.
The approval to the drug has come at a time when India has been grappling with a record-breaking wave of coronavirus pandemic that has stretched the country s healthcare infrastructure to its limit. In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation.